Results 221 to 230 of about 181,087 (306)

Chimeric Antigen Receptor Cell Therapy: Current Status and Its Potential in Aging and Alzheimer's Disease. [PDF]

Int J Mol Sci
Jurcau MC, Iovanovici CD, Jurcau A, Militaru M, Udrea RB, Comanescu A, Nunkoo VS.   +6 more
europepmc   +1 more source

Respiratory Syncytial Virus Under the Lens of Structure: From Prefusion Stabilization to Next‐Generation Immunotherapies

iNew Medicine, EarlyView.
This illustration integrates key concepts covered in the review, including high‐risk populations, viral structure, host entry factors, the replication cycle, and licensed antibody‐based prevention strategies. ABSTRACT Respiratory syncytial virus (RSV) is a negative‐sense RNA virus belonging to the genus Orthopneumovirus within the family Pneumoviridae.
Zekai Cheng, Qianqian Wang, Jiachen Zhang, Sandra Chiu   +3 more
wiley   +1 more source

Breakthrough for Anticancer Immunotherapy: Current Advances in Manufacturing Protocols of Chimeric Antigen Receptor-Based Therapies. [PDF]

Antibodies (Basel)
Qian Y, Ma W, Xu XN.
europepmc   +1 more source

Gastrointestinal manifestations following chimeric antigen receptor T‐cell (CAR‐T) 19 therapy in pediatric patients with CD19+ acute lymphoblastic leukemia

JPGN Reports, EarlyView.
Abstract Pediatric patients with CD19+ acute lymphoblastic leukemia (ALL) undergoing chimeric antigen receptor T‐cell (CAR‐T) therapy frequently experience gastrointestinal (GI) complications. A retrospective study analyzed 13 patients (median age: 8 years) treated between January 2020 and January 2024.
Judith Raya Muñoz, Melissa Panesso Romero, Saray Mesonero Cavia, Marta Freixas Bermejo, Vanessa Cabello Ruiz, Marina Álvarez Beltran, Maria Cristina Díaz de Heredia Rubio, Susana Elena Redecillas Ferreiro, Oscar Segarra Canton   +8 more
wiley   +1 more source

Chimeric antigen receptor cells as a tool for localized delivery of TNFα in solid cancer treatment. [PDF]

Hum Vaccin Immunother
Yao Z, Sittplangkoon C.
europepmc   +1 more source

Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis. [PDF]

Transplant Cell Ther
Nadiminti KV, Ahn KW, Patel J, Lian Q, Bezerra E, Chen A, Ganguly S, Gergis U, Hashmi H, Kharfan-Dabaja MA, Kuruvilla J, Lekakis L, Locke FL, Murthy H, Mousthafa MA, Perales MA, Pophali P, Riedell PA, Shah NN, Wang T, Pasquini M, Hamadani M, Turtle CJ, Herrera AF, Shadman M.   +24 more
europepmc   +1 more source

CRISPR Enabled Precision Oncology: From Gene Editing to Tumor Microenvironment Remodeling

Med Research, EarlyView.
CRISPR technology has progressed from a prokaryotic immune system to a diverse suite of editing platforms, including Cas nucleases, base and prime editors, and RNA‐targeting enzymes. These advances enable precise genomic and epigenomic interventions, high‐throughput functional screening, and immune engineering.
Kailai Li, Peixin Huang, Yue Qian, Anqi Lin, Jingjun He, Junyi Shen, Li Chen, Kai Miao, Jian Zhang   +8 more
wiley   +1 more source

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma. [PDF]

J Hematol Oncol
Kaulen LD, Karschnia P, Doubrovinskaia S, Abramson JS, Soumerai JD, Martinez-Lage M, Haydu JE, Shankar GM, Patel C, Choi BD, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Wick W, Maus MV, Chen YB, Frigault MJ, Dietrich J.   +18 more
europepmc   +1 more source

Tumor Organoids: Breakthroughs in Clinical Decision Making, Drug Development, and Translational Advances Beyond Conventional Models

Med Research, EarlyView.
ABSTRACT Tumor organoid models are revolutionizing cancer research by bridging the translational gap between conventional two‐dimensional cell cultures and animal models. This Editorial thoroughly explores the fundamental innovations of patient‐derived organoid technology.
Yimao Wu, Ruowei Sun, Gokhan Zengin, Shuai Ren, Meng‐Yao Li   +4 more
wiley   +1 more source